“I spent 20 years trying to do immunotherapy and we weren’t as successful as we wanted to be probably because we didn’t recognize the degree to which the environment within the tumor is so suppressive,” said Dr. Dan Sterman during our latest Meet the Mesothelioma Experts broadcast referring to the inability of the immune system […]
Mesothelioma researcher and Meso Foundation grant recipient Prasad S. Adusumilli, MD, FACS, FCCP, of the Memorial Sloan Kettering Cancer Center (MSKCC) was an author on the review article CAR T-cell therapy for lung cancer and malignant pleural mesothelioma recently published in Translational Research: The Journal of Laboratory and Clinical Medicine.
Dr. Adusumilli is a thoracic surgeon-scientist […]
Joseph R. Testa, PhD, of the Fox Chase Cancer Center has edited a newly published book titled “Asbestos and Mesothelioma” to serve as a resource for researchers and medical professionals in the field. Mary Hesdorffer, NP, Executive Director at the Meso Foundation co-authored one of the book’s chapters.
More information about the book follows:
“Asbestos and Mesothelioma,” […]
In 2015, data was presented at the American Society of Clinical Oncology (ASCO) Annual Meeting from a Phase III French study that demonstrated improved survival rates for patients who received bevacizumab (Avastin® Genentech, Inc.) in addition to the standard chemotherapy regimen of pemetrexed/cisplatin.
The outcome of the study prompted the independent French cooperative group and Genentech […]
The April 2017 issue of Translational Lung Cancer Research features an article titled Immunotherapy and radiation therapy for malignant pleural mesothelioma written by a group of investigators known within the Meso Foundation’s community: Evan W. Alley, MD, PhD, Sharyn I. Katz, MD, and Keith A. Cengel, MD, PhD, of the University of Pennsylvania, and Charles […]